Germline breast cancer susceptibility gene mutations and breast cancer outcomes

[1]  Y. Miki,et al.  Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations , 2017, Cancer science.

[2]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[3]  G. Pond,et al.  Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry , 2017, Journal of Medical Genetics.

[4]  P. Kronqvist,et al.  Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors , 2016, British Journal of Cancer.

[5]  J. Garber,et al.  Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care , 2016, Breast Cancer Research and Treatment.

[6]  S. Merajver,et al.  Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. , 2016, Seminars in oncology.

[7]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[8]  R. Scott,et al.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Generali,et al.  A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial. , 2016, Future oncology.

[10]  kConFab investigators,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016 .

[11]  Yuan Xue,et al.  Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing , 2016, Cancer biology & medicine.

[12]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[13]  Chiun-Sheng Huang,et al.  Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer , 2016, Oncotarget.

[14]  P. Ang,et al.  Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore , 2016, npj Genomic Medicine.

[15]  A. Galli,et al.  MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers. , 2015, European journal of medical genetics.

[16]  Yuya Kobayashi,et al.  Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.

[17]  D. Evans,et al.  Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study , 2015, Journal of Medical Genetics.

[18]  Fabrice Kwiatkowski,et al.  DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition. , 2015, American journal of cancer research.

[19]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[20]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Frank Reinecke,et al.  Quantitative analysis of differences in copy numbers using read depth obtained from PCR-enriched samples and controls , 2015, BMC Bioinformatics.

[22]  Tatiana Popova,et al.  Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data , 2014, Bioinform..

[23]  J. Hopper,et al.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study , 2014, Breast Cancer Research.

[24]  P. Brown,et al.  Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data , 2014, Breast Cancer Research and Treatment.

[25]  Yuya Kobayashi,et al.  Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[27]  Haeyoung Kim,et al.  Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer , 2013, Journal of breast cancer.

[28]  Jicheng Li,et al.  Hereditary Breast Cancer in the Han Chinese Population , 2013, Journal of epidemiology.

[29]  D. West,et al.  Abstract P4-11-02: NovelBRCA1andBRCA2genomic rearrangements in Southern Chinese breast/ovarian cancer patients , 2012 .

[30]  D. West,et al.  Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients , 2012, Breast Cancer Research and Treatment.

[31]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[32]  L. Aaltonen,et al.  A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer , 2012, Journal of Medical Genetics.

[33]  D. Ikeda,et al.  Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations , 2012, Familial Cancer.

[34]  Yuntao Xie,et al.  Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer , 2012, Breast Cancer Research and Treatment.

[35]  King-Jen Chang,et al.  Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer , 2012, Journal of Human Genetics.

[36]  Samantha E. Boyle,et al.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients , 2012, Hereditary Cancer in Clinical Practice.

[37]  C. Isaacs,et al.  BRCA Mutation Testing in Determining Breast Cancer Therapy , 2011, Cancer journal.

[38]  A. Mannermaa,et al.  Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility , 2011, Breast Cancer Research and Treatment.

[39]  P. Pérez-Segura,et al.  A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families , 2011, Breast Cancer Research and Treatment.

[40]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[41]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[42]  W. Han,et al.  Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population , 2009, Familial Cancer.

[43]  Z. Shao,et al.  Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients , 2009, Breast Cancer Research and Treatment.

[44]  Alfons Meindl,et al.  Breast cancer susceptibility: current knowledge and implications for genetic counselling , 2009, European Journal of Human Genetics.

[45]  Ofra Barnett-Griness,et al.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.

[46]  D. Evans,et al.  Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening , 2007, Journal of Medical Genetics.

[47]  J. Klijn,et al.  Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.

[48]  Shunsuke Kato,et al.  Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods , 2006, Nucleic acids research.

[49]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[50]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[51]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[52]  Karla Bowles,et al.  Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.

[53]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[54]  P. Goodwin,et al.  Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.

[55]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[56]  F. Liebens,et al.  Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. , 2007, European journal of cancer.